List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9646399/publications.pdf Version: 2024-02-01

236925 123424 4,301 92 25 61 citations h-index g-index papers 96 96 96 8004 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematology,the, 2020, 7, e575-e582.	4.6	848
2	The RAG Proteins and V(D)J Recombination: Complexes, Ends, and Transposition. Annual Review of Immunology, 2000, 18, 495-527.	21.8	571
3	American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Advances, 2021, 5, 872-888.	5.2	310
4	Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews Cardiology, 2021, 18, 194-209.	13.7	304
5	A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances, 2021, 5, 1164-1177.	5.2	241
6	Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine, 2021, 27, 1178-1186.	30.7	183
7	Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019. Chest, 2020, 158, 1397-1408.	0.8	177
8	Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology, 2021, 6, .	11.9	153
9	Intermediateâ€dose anticoagulation, aspirin, and inâ€hospital mortality in <scp>COVID</scp> â€19: A propensity scoreâ€matched analysis. American Journal of Hematology, 2021, 96, 471-479.	4.1	129
10	Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infectious Diseases, The, 2021, 21, 1485-1486.	9.1	125
11	Circulating markers of angiogenesis and endotheliopathy in COVIDâ€19. Pulmonary Circulation, 2020, 10, 1-4.	1.7	103
12	Anemia in Pregnancy. Hematology/Oncology Clinics of North America, 2011, 25, 241-259.	2.2	85
13	A Functional Analysis of the Spacer of V(D)J Recombination Signal Sequences. PLoS Biology, 2003, 1, e1.	5.6	67
14	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal of Hepatology, 2021, 75, 647-658.	3.7	67
15	Systematic review of May-Thurner syndrome with emphasis on gender differences. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2018, 6, 399-407.e4.	1.6	62
16	Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal of Investigative Dermatology, 2017, 137, 951-954.	0.7	61
17	Whole-exome sequencing in evaluation of patients with venous thromboembolism. Blood Advances, 2017, 1, 1224-1237.	5.2	55
18	SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood, 2022, 139, 1564-1574.	1.4	55

#	Article	IF	CITATIONS
19	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis. Blood Advances, 2022, 6, 664-671.	5.2	53
20	Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight, 2021, 6, .	5.0	49
21	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients. Blood Advances, 2021, 5, 3951-3959.	5.2	49
22	Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood, 2021, 137, 969-976.	1.4	46
23	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances, 2022, 6, 4915-4923.	5.2	42
24	Thrombocytopenia. Primary Care - Clinics in Office Practice, 2016, 43, 543-557.	1.6	35
25	Ischemic Stroke, Inflammation, and Endotheliopathy in COVID-19 Patients. Stroke, 2021, 52, e233-e238.	2.0	31
26	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. JAAD Case Reports, 2019, 5, 1018-1026.	0.8	24
27	American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 2022, 6, 4975-4982.	5.2	21
28	A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences. , 2022, 1, 223-237.		20
29	Trends and factors affecting the US adult hematology workforce: a mixed methods study. Blood Advances, 2019, 3, 3550-3561.	5.2	18
30	Transfusion Medicine and the Pregnant Patient. Hematology/Oncology Clinics of North America, 2011, 25, 393-413.	2.2	17
31	Associations between hematology/oncology fellows' training and mentorship experiences and hematology-only career plans. Blood Advances, 2019, 3, 3278-3286.	5.2	17
32	Risk factors for presence and severity of pulmonary embolism in patients with deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2018, 6, 7-12.	1.6	14
33	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 766-770.e4.	0.4	13
34	An Update on the "Novel―and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy. Clinics in Chest Medicine, 2018, 39, 583-593.	2.1	11
35	Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances, 2020, 4, 539-545.	5.2	11
36	The Hidden Lesion. New England Journal of Medicine, 2016, 375, 1198-1199.	27.0	9

#	Article	IF	CITATIONS
37	Statin therapy associated with improved thrombus resolution in patients with deep vein thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2019, 7, 169-175.e4.	1.6	9
38	Cerebral venous sinus thrombosis after vaccination: the UK experience. Lancet, The, 2021, 398, 1107-1109.	13.7	9
39	Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. JCO Oncology Practice, 2022, 18, e586-e599.	2.9	9
40	The Hidden Lesion. New England Journal of Medicine, 2016, 374, 2160-2165.	27.0	8
41	Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. Oxford Medical Case Reports, 2014, 2014, 138-140.	0.4	7
42	Adverse Events of Injectable Deoxycholic Acid. Dermatologic Surgery, 2020, 46, 942-949.	0.8	7
43	Association of obesity with venous thromboembolism and myocardial injury in COVID-19. Obesity Research and Clinical Practice, 2021, 15, 512-514.	1.8	7
44	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. PLoS Biology, 2021, 19, e3001373.	5.6	7
45	Costâ€effectiveness of secondâ€line therapies in adults with chronic immune thrombocytopenia. American Journal of Hematology, 2023, 98, 122-130.	4.1	7
46	Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism. Blood, 2018, 132, 2506-2506.	1.4	6
47	Impact of COVID-19 on Hematology-Oncology Fellowship Programs: A Quantitative and Qualitative Survey Assessment of Fellowship Program Directors. JCO Oncology Practice, 2022, 18, e551-e563.	2.9	6
48	Perniolike lesions and coagulopathy in a patient with COVID-19 infection. JAAD Case Reports, 2020, 6, 1294-1296.	0.8	5
49	Heparin-Induced Thrombocytopenia and Cardiac Surgery: A Role for Hematologists in Critical Care Units. Blood, 2011, 118, 2062-2062.	1.4	4
50	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood, 2015, 126, 1138-1138.	1.4	4
51	Clinical characteristics, time course, and outcomes of major bleeding according to bleeding site in patients with venous thromboembolism. Thrombosis Research, 2022, 211, 10-18.	1.7	4
52	Association of renalase with clinical outcomes in hospitalized patients with COVID-19. PLoS ONE, 2022, 17, e0264178.	2.5	4
53	Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network metaâ€analysis, and decision analysis. Journal of Evaluation in Clinical Practice, 2020, 26, 7-17.	1.8	3
54	Cryptic Cachexia. New England Journal of Medicine, 2020, 383, 68-74.	27.0	3

#	Article	IF	CITATIONS
55	Accurate accounting of caplacizumab cost effectiveness. Lancet Haematology,the, 2021, 8, e315.	4.6	3
56	Factors Influencing Hematology Career Choice in Hematology and Oncology Fellows at a Major Academic Institution. Blood, 2016, 128, 3538-3538.	1.4	3
57	<i>Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment</i> . Blood, 2020, 136, 20-21.	1.4	3
58	Intravascular Large B-Cell Lymphoma: Clinical and Histopathologic Findings. Yale Journal of Biology and Medicine, 2020, 93, 35-40.	0.2	3
59	The case for classical haematology: the impact of a name and the future of a field. Lancet Haematology,the, 2022, 9, e455-e459.	4.6	3
60	Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances, 2023, 7, 3058-3068.	5.2	3
61	Characteristics of provoked deep venous thrombosis in a tertiary care center. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2017, 5, 477-484.	1.6	2
62	Acute Limb Ischemia in an 8-Year-Old Patient: A Case Report. Annals of Vascular Surgery, 2018, 51, 327.e1-327.e8.	0.9	2
63	Evaluation of Polycythemia. JAMA Internal Medicine, 2018, 178, 128.	5.1	2
64	Internal medicine trainees' knowledge and confidence in using the American Society of Hematology Choosing Wisely guidelines in hemostasis, thrombosis, and non-malignant hematology. PLoS ONE, 2018, 13, e0197414.	2.5	2
65	A novel approach to the program evaluation committee. BMC Medical Education, 2019, 19, 465.	2.4	2
66	Immunothrombosis: a COVIDâ€19 concerto. British Journal of Haematology, 2021, 194, 491-493.	2.5	2
67	Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3814-3814.	1.4	2
68	The Use of Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients. Blood, 2015, 126, 4728-4728.	1.4	2
69	Whole-Exome Sequencing in Evaluation of Thrombophilia: Characterization of Novel Genetic Variants. American Journal of Clinical Pathology, 2019, 152, S35-S35.	0.7	1
70	The next(gen) step in coagulation testing. Blood, 2019, 134, 2002-2003.	1.4	1
71	Andexanet Alfa: Considerations and Practical Applications. Critical Pathways in Cardiology, 2019, 18, 200-206.	0.5	1
72	Spontaneous recovery in a patient with acquired thrombotic thrombocytopenic purpura (TTP): observation of a †subclinical' TTP state. Hematology, 2020, 25, 473-477.	1.5	1

#	Article	IF	CITATIONS
73	Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases. Journal of Thrombosis and Thrombolysis, 2021, 52, 854-862.	2.1	1
74	A Brewing Back Pain. New England Journal of Medicine, 2021, 385, 66-72.	27.0	1
75	Using the Rothman Index to Predict Discharge and Readmission Rates in an Inpatient Hematology Unit. Blood, 2014, 124, 1302-1302.	1.4	1
76	Predictive Value of Rothman Index in Patients That Develop Febrile Neutropenia. Blood, 2015, 126, 2107-2107.	1.4	1
77	Whole Exome Sequencing in Evaluation of Thrombophilia: A Novel 33-Gene Panel. Blood, 2015, 126, 3529-3529.	1.4	1
78	Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood, 2015, 126, 3275-3275.	1.4	1
79	Mentorship Experiences Among Second-Year U.S. Hematology/Oncology Fellows in the 2019 ASH Hematology/Oncology Fellows Survey. Blood, 2019, 134, 2124-2124.	1.4	1
80	Multiâ€system complications of hypereosinophilia. American Journal of Hematology, 2016, 91, 444-447.	4.1	0
81	Reply. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2018, 6, 560-561.	1.6	0
82	Clinical Significance of Coagulation Studies in Predicting Response to Recombinant Factor VIIa in Cardiac Surgery Patients. Blood, 2011, 118, 4351-4351.	1.4	0
83	Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Blood, 2015, 126, 4455-4455.	1.4	0
84	A Novel Approach to the Medical Student Hematology Curriculum. Blood, 2016, 128, 3537-3537.	1.4	0
85	Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood, 2018, 132, 5810-5810.	1.4	0
86	Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood, 2018, 132, 2284-2284.	1.4	0
87	Anemia Is Negatively Correlated with Cardiac Index in Hereditary Hemorrhagic Telangiectasia(HHT) Patients with Liver Arteriovascular Malformations (AVMs). Blood, 2019, 134, 4811-4811.	1.4	0
88	Hematology/Oncology Fellows' Future Plans and Job Expectations: Findings from the 2019 Hematology/Oncology Fellows Survey. Blood, 2019, 134, 5780-5780.	1.4	0
89	Perceptions and Attitudes Toward Single-Board Hematology Training in the United States: A Program Director Survey. Blood, 2019, 134, 3392-3392.	1.4	0
90	Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey. Blood, 2019, 134, 2097-2097.	1.4	0

#	Article	IF	CITATIONS
91	Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center. Blood, 2019, 134, 5569-5569.	1.4	ο
92	Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis. Blood, 2021, 138, 777-777.	1.4	0